ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Understanding the functional inflammatory factors involved in therapeutic response to immune checkpoint inhibitors for pan-cancer

Wu, Yanmeizhi; Yu, Shan*; Qiao, Hong*哈尔滨医科大学
Frontiers in Pharmacology2022-9-1DOI: 10.3389/fphar.2022.990445
3被引6阅读
引用收藏
分享

摘要

Immune checkpoint inhibitors (ICIs) fight tumor progression by activating immune conditions. The inflammatory factors are playing a functional role in programmed death-1 (PD-1) or other immune checkpoints. They are involved in regulating the expression of programmed death ligand-1 (PD-L1), the only predictor recognized by the guidelines in response to ICIs. In addition, abundant components of the tumor microenvironment (TME) all interact with various immune factors contributing to the response to ICIs, including infiltration of various immune cells, extracellular matrix, and fibroblasts. Notably, the occurrence of immune-related adverse events (irAEs) in patients receiving ICIs is increasingly observed in sundry organs. IrAEs are often regarded as an inflammatory factor-mediated positive feedback loop associated with better response to ICIs. It deserves attention because inflammatory factors were observed to be different when targeting different immune checkpoints or in the presence of different irAEs. In the present review, we address the research progresses on regulating inflammatory factors for an intentional controlling anti-cancer response with immune checkpoint inhibitors.

学科与关键词

关键词
immune checkpoint inhibitorsinflammatory factorsprogrammed death-1immune-related adverse eventstumor microenvironment
相关
加载中…
  • New developments in the mechanism and application of immune checkpoint inhibitors in cancer therapy (Review)
    Wang, Yanjun; Yang, Shuo; Wan, Li; Ling, Wei; Chen, Hao*; Wang, Jinghua*International Journal of Oncology, 2023, 63(1): 86.被引 3
  • Biomarkers related to immune checkpoint inhibitors therapy
    Li, Na; Hou, Xin; Huang, Shaogang; Tai, Risheng; Lei, Lei; Li, Siyu; Abuliz, Adina; Wang, Geng*; Yang, Shanru*Biomedicine and Pharmacotherapy, 2022, 147: 112470.被引 9
  • Adverse and unconventional reactions related to immune checkpoint inhibitor therapy for cancer
    Li, Na; Wang, Geng; Hou, Xin; Tai, Risheng; Huang, Shaogang; He, Zhize; Lei, Lei; Xu, Suling*; Yang, Shanru*International Immunopharmacology, 2022, 108: 108803.被引 4
查看全部 →

发表信息

论文状态
公开发表
期刊
Frontiers in Pharmacology
发表日期
2022-09-01
卷期
第 13 卷
页码
990445
DOI
10.3389/fphar.2022.990445
语言
ENGLISH
期刊等级
2区
成果收录
SCIE

作者

  • W

    Wu, Yanmeizhi (第一作者)

    2 · harbin med univ

  • Y

    Yu, Shan (通讯)

    2 · harbin med univ

查看全部 3 位作者收起作者
  • Q

    Qiao, Hong (通讯)

    2 · harbin med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417